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life expectancy (QALE), cumulative complication incidences and
total management costs (drug costs plus complications) over 10
years. The model combined a series of interdependent time- and
state-based Markov sub-models of diabetes-related complica-
tions, incorporating 2nd order Monte-Carlo simulation. Future
outcomes were discounted at 3% per annum (US Medicare per-
spective). Sensitivity analyses were performed. RESULTS: At
follow-up, HbA1C was reduced 0.59% from baseline, fasting
blood glucose (FBG) was more tightly controlled (−25 mg/dL),
with mean weight loss of 0.78 kg. Daily dose remained stable
upon replacing glargine (27.3 U vs. 23.8 U). Rate of all hypo-
glycaemia decreased by 728 events per 100 patient years from
baseline, with major and nocturnal reduced by 26 and 208
events/100 patient years, respectively. Long-term projections
indicated these clinical beneﬁts increased LYG (0.07 years) and
QALE (0.31 years). Direct medical costs were $2020 less 
per patient (10 years), largely due to reduced incidence rates 
of complications, predominantly renal and cardiovascular.
CONCLUSION: Patients with type 2 diabetes may experience
clinical outcome beneﬁts when using insulin detemir compared
to glargine. These beneﬁts were projected to reduce treatment
costs and increase QALE through a reduction of diabetes-related
complications.
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OBJECTIVES: Evidence-based measures are necessary in
medical decision-making when comparing modern therapy
options with long-established treatments. As such, data from
naturalistic settings provide important insight to use of such
treatments in actual clinical practice. This study aimed to project
real-life economic and clinical implications of converting type 2
diabetes patients on NPH basal-oral therapy to insulin detemir.
METHODS: Pre-transfer, baseline and end-of-study data for 251
subjects converting from NPH ± orals to detemir ± orals were
analyzed. Patients were an enrolled subgroup of a multi-national,
prospective observational trial (51% male; mean age 61.5 years;
diabetes duration 9 years; HbA1c 7.8%; BMI 30.9 kg/m2). Total
treatment costs (annual drug plus complications), life years
gained (LYG), quality-adjusted life expectancy (QALE), and
cumulative complication incidences were assessed using a vali-
dated model of diabetes-related complications. Fifteen intercon-
nected Markov sub-models employed second order Monte Carlo
simulation and non-parametric bootstrapping (1000 × 1000) to
estimate long-term outcomes (10 year horizon; US Medicare per-
spective), discounted at 3% per annum. Sensitivity analyses were
performed. RESULTS: At 12 weeks post-transfer, mean absolute
HbA1c was reduced 0.58%, with improved fasting blood
glucose (−28 mg/dL) and weight reduction (0.87 kg). Observa-
tion period daily dose did not differ considerably to pre-transfer
NPH (27.8 U vs. 25.7 U). Use of orals remained similar upon
conversion. A reduced rate of all hypoglycaemia (pre- vs. post-
transfer) was observed (−663 events/100 patient years), as were
major and nocturnal episodes (39 and 429 events/100 patient
years, respectively). Clinical beneﬁts led to projected increases in
LYG (0.07 years) and QALE (0.30 years), with associated total
management costs reduced $2416 per patient, primarily from
reductions in major hypoglycaemia and complication risks
(notably ocular and cardiovascular). CONCLUSION: Improved
glycaemic control and reduced hypoglycaemia were observed 
in patients with type 2 diabetes transferring from NPH-based
therapy to detemir, generating projected improvements in
quality-adjusted life expectancy and total costs.
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OBJECTIVES: Many patients with type 2 diabetes are not
achieving recommended HbA1c targets. Barriers preventing the
initiation of more efﬁcacious therapies include economic restric-
tions. The present analysis aimed to evaluate potential clinical
and economic outcomes of initiating insulin detemir among type
2 diabetes patients previously on oral medication alone.
METHODS: Data were analyzed from 1321 patients who par-
ticipated in a 12-week prospective observational trial (50.6%
male; mean age 62.2 years; diabetes duration 6.5 years; HbA1c
8.49%; BMI 29.5 kg/m2). A published and validated simulation
model of diabetes projected total treatment costs (annual drug
plus complications), life years gained (LYG), quality-adjusted life
expectancy (QALE), and complication incidences for patients
commencing detemir versus those modelled to remain insulin
naïve (10 year horizon). The model structure combines 15 inter-
dependent Markov sub-models, simulating the progression of
diabetes-related complications and utilizing second order Monte
Carlo simulation to account statistical uncertainty at the patient
and parameter levels. Outcomes were discounted at 3% per
annum (US Medicare perspective). Sensitivity analyses were 
performed. RESULTS: Initiation of detemir generated a 1.29%
mean reduction in HbA1c over 3 months, with improved fasting
blood glucose (FBG; total (SD): −58 mg/dL (−8.2 mg/dL)), and
no signiﬁcant increase in the occurrence of hypoglycaemia. At
follow-up, 16% of patients discontinued or reduced oral med-
ications. Pharmacoeconomic modelling demonstrated detemir
treatment to improve LYG (0.156 years) and QALE (0.173
years). Reduced major complication incidences were also esti-
mated, including vascular, ocular, and renal events. An incre-
mental cost-effectiveness ratio (ICER) of $657 per QALY gained
was generated. An acceptability curve (willingness-to-pay of
$50,000/QALY) revealed detemir to have a 95.5% chance of
being cost-effective. CONCLUSION: Considerable short-term
clinical beneﬁts were observed among insulin-naïve type 2
patients initiating detemir. Long-term treatment with detemir
was predicted to increase quality-adjusted outcomes and reduce
diabetic complications in a cost-effective manner.
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OBJECTIVES: The US NHANES study reveals that most type 
2 diabetes patients are not achieving endorsed HbA1c goals.
During disease progression, clinicians treating insulin-naïve sub-
jects may optimize continued oral therapy, or prescribe exoge-
nous insulin to induce tighter glycaemic control. The present
analysis aimed to estimate long-term clinical and economic out-
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comes of adding biphasic insulin aspart 30 to metformin and
pioglitazone (BIAsp30 + met + pio) compared to maintaining
optimized oral therapy alone (met + pio). METHODS: Treat-
ment efﬁcacy, safety, and baseline demographic data of patients
randomized to either therapy were derived from a recent 34-
week controlled trial (n = 200; mean age 53.8 years; baseline
HbA1c 8.1%; BMI 32.9 kg/m2; 42% male). Over the trial
period, signiﬁcant improvements in HbA1c were demonstrated
for BIAsp30 + met + pio (−1.5 % between arms; p < 0.0001),
though minor hypoglycaemia increased (p < 0.01). A validated
and peer-reviewed economic model utilizing 2nd order Monte-
Carlo simulation with tracker variables and non-parametric
bootstrapping (15 interdependent Markov sub-models of dia-
betes-related complications) calculated life expectancy (LE),
quality-adjusted life expectancy (QALE), incremental cost-effec-
tiveness (ICER), and cumulative complication events over 35
years (base-case). Total management costs were calculated
(annual pharmacy plus complication; US Medicare perspective).
Clinical and cost outcomes were discounted at 3% per annum.
Sensitivity analyses were performed. RESULTS: End-of-study
clinical improvements demonstrated with BIAsp30 were pro-
jected to increase LE (0.66 years), QALE (0.55 quality-adjusted
life years (QALYs)), and reduce cumulative incidences of dia-
betes-related complications, notably retinopathy, renal, and 
cardiovascular disease. An ICER of $22,209/QALY gained was
generated, with an acceptability curve (willingness-to-pay of
$50,000/QALY) portraying BIAsp30 to have a 98.4% probabil-
ity of being cost-effective. Sensitivity analyses supported these
results. CONCLUSION: Type 2 diabetes patients may signiﬁ-
cantly improve glycaemic control with BIAsp30 versus optimiz-
ing oral therapy alone. Through long-term health outcome
projections, BIAsp30 was estimated to improve quality-adjusted
life expectancy and reduce diabetes-related complications in a
cost-effective manner.
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OBJECTIVE: To estimate the cost-effectiveness of inhaled
insulin (INH) in Type 1 (T1DM) and Type 2 diabetes mellitus
(T2DM) patients uncontrolled on current treatment.
METHODS: Cost-effectiveness analysis was conducted from
Swedish health care perspective using the Economic Assessment
of Glycemic control and Long-term Effects of diabetes (EAGLE)
simulation model. EAGLE uses risk equations for the probabil-
ity of micro- and macrovascular complications derived from
UKPDS, WESDR and DCCT. Patient characteristics were
obtained from the Swedish National Diabetes Registry. Compli-
cation costs and health-state utilities were taken from the litera-
ture. Equivalent efﬁcacy was assumed for inhalation and
standard insulin regimens. INH was assumed to result in earlier
initiation or better intensiﬁcation of insulin therapy. Data on
intensiﬁcation inertia were taken from a retrospective study and
intensiﬁcation differential (between INH and standard treat-
ment) was taken from published literature. The analysis was 
performed over a 20 y time-horizon. Costs (SEK2005) and
quality-adjusted life-years (QALYs) were discounted by 3% 
per annum. RESULTS: Treatment costs were higher for all sub-
groups using INH, while the costs of complications were lower,
and survival and utility higher. ICER’s for INH compared to
staying uncontrolled on basal-bolus for T1DM and T2DM were
SEK 38,948 and SEK 151,186/QALY, respectively. In T2DM
patients uncontrolled on °Y´2 orals ICER’s for INH compared to
intensifying to basal or mix-insulin were SEK 178106 and SEK
16,2294/QALY, respectively. For patients uncontrolled on basal
insulin ICER’s for INH compared to intensifying either to mix-
insulin or basal-bolus were 265,376 and 232,442SEK/QALY,
respectively; and in patients on mix-insulin the ICER’s for INH
compared to intensifying to basal-bolus were 183,132SEK/
QALY. Results were robust to changes in discount rate and inten-
siﬁcation differential, although more sensitive to the level of
treatment-associated utilities. CONCLUSION: For T1DM and
T2DM patients uncontrolled on current treatment, a regimen
including INH appears to be cost-effective when taking long-
term micro- and macrovascular outcomes into account.
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OBJECTIVES: The largest proportion of costs in diabetes is due
to complications of the disease. Hypoglycaemia is a common,
chronic complication of drug treatment in diabetes. The aim of
this study was to survey the cost of a major hypoglycaemic event.
METHODS: A systematic literature review was carried out on
all relevant assessments found in published literature. A study
was regarded relevant if it included the cost of a major hypo-
glycaemic event. RESULTS: Relevant studies were found in 
the following countries: Canada, Germany, Sweden, Switzerland,
UK and US. Five studies collected primary data and six studies
based the cost of a hypoglycaemic event on assumptions around
treatment patterns. A major hypoglycaemic event was deﬁned
differently in the different studies. Four studies deﬁned the state
as requiring third-party medical intervention which means assis-
tance from health care services with costs ranging from €293 to
€586. The state was also deﬁned as requiring third party assis-
tance by medical and/or family assistance in four studies, these
estimates ranged from €190 to €1643. One study deﬁned the
state as requiring assistance from another person excluding
medical intervention (€69), while two studies deﬁned the state
from the ICD-9-CM codes, which requires a visit to a health care
provider and presented costs at €950 and €4083, respectively.
The difference in costs between the studies can be explained by
different health care systems, whether direct and/or indirect costs
were included and whether hospitalisation was excluded. Indi-
rect costs were included in three studies. CONCLUSIONS:
Which costs to include in a study is determined by which deﬁn-
ition of a major hypoglycaemic event that is chosen. For this
reason it is important that health economic models apply
matched deﬁnitions to the clinical studies they are modelling.
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OBJECTIVES: The present analysis estimated overall annual
inpatient and outpatient costs incurred by Swedish patients with
diabetes mellitus between 2000 and 2004 based on data from
the RECAP study, which included medical records on 13,873
patients with diabetes mellitus retrospectively identiﬁed in com-
puterised registers at 26 primary care centres in Uppsala county.
Patients included in the study fulﬁlled at least one of the fol-
